StockData
Johnson & Johnson logo

Johnson & Johnson (JNJ) stock

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3086% above fair value
$278.70−3.85 (-1.36%)

Close on Nov 17, 2026Market cap $670.92BP/E 42.3Yield 1.84%

Johnson & Johnson r&d expenses

Research and development expenses are spending on new products and technology.

Johnson & Johnson's R&D Expenses for the twelve months ending Oct 1, 2023 was $14.78B, down 3.8% year over year. For fiscal 2025 it was $109.00M, down 94.1% from the year before. Over ten years it grew -35.7% a year on average. The highest annual figure on record is $12.16B in fiscal 2020.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 28, 2025$109.00M-94.1%
FY2024Dec 29, 2024$1.84B+281.2%
FY2023Dec 31, 2023$483.00M–
FY2022Jan 1, 2023$0–
FY2021Jan 2, 2022$0-100.0%
FY2020Jan 3, 2021$12.16B+7.1%
FY2019Dec 29, 2019$11.36B+5.4%
FY2018Dec 30, 2018$10.78B+1.7%
FY2017Dec 31, 2017$10.59B+15.9%
FY2016Jan 1, 2017$9.14B+1.1%
FY2015Jan 3, 2016$9.05B+6.5%
FY2014Dec 28, 2014$8.49B+3.8%
FY2013Dec 29, 2013$8.18B+6.8%
FY2012Dec 30, 2012$7.67B+1.6%
FY2011Jan 1, 2012$7.55B+10.3%
FY2010Jan 2, 2011$6.84B-2.0%
FY2009Jan 3, 2010$6.99B-7.8%
FY2008Dec 28, 2008$7.58B-1.3%
FY2007Dec 30, 2007$7.68B–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 27, 2026$4.65B+32.3%
Q2 FY2026Jun 28, 2026$3.65B+13.3%
Q1 FY2026Mar 29, 2026$3.53B-28.8%
Q3 FY2025Sep 28, 2025$3.67B+6.7%
Q2 FY2025Jun 29, 2025$3.52B-0.7%
Q1 FY2025Mar 30, 2025$3.23B-6.4%
Q3 FY2024Sep 29, 2024$4.95B+33.7%
Q2 FY2024Jun 30, 2024$3.44B-0.4%
Q1 FY2024Mar 31, 2024$3.54B-15.2%
Q3 FY2023Oct 1, 2023$3.45B-1.1%
Q2 FY2023Jul 2, 2023$3.70B0.0%
Q1 FY2023Apr 2, 2023$3.46B-0.2%
Q4 FY2022Jan 1, 2023$4.18B-11.5%
Q3 FY2022Oct 2, 2022$3.49B+1.8%
Q2 FY2022Jul 3, 2022$3.70B+9.1%
Q1 FY2022Apr 3, 2022$3.46B+8.9%
Q4 FY2021Jan 2, 2022$4.72B+17.1%
Q3 FY2021Oct 3, 2021$3.42B+20.5%
Q2 FY2021Jul 4, 2021$3.39B+25.4%
Q1 FY2021Apr 4, 2021$3.18B+23.2%
Q4 FY2020Jan 3, 2021$4.03B+24.8%
Q3 FY2020Sep 27, 2020$2.84B+9.3%
Q2 FY2020Jun 28, 2020$2.71B+1.5%
Q1 FY2020Mar 29, 2020$2.58B-9.7%
Q4 FY2019Dec 29, 2019$3.23B+0.2%
Q3 FY2019Sep 29, 2019$2.60B+3.6%
Q2 FY2019Jun 30, 2019$2.67B+1.0%
Q1 FY2019Mar 31, 2019$2.86B+18.9%
Q4 FY2018Dec 30, 2018$3.22B-11.5%
Q3 FY2018Sep 30, 2018$2.51B-3.0%
Q2 FY2018Jul 1, 2018$2.64B+14.9%
Q1 FY2018Apr 1, 2018$2.40B+16.1%
Q4 FY2017Dec 31, 2017$3.64B+35.5%
Q3 FY2017Oct 1, 2017$2.59B–
Q2 FY2017Jul 2, 2017$2.30B–
Q1 FY2017Apr 2, 2017$2.07B–
Q4 FY2016Jan 1, 2017$2.69B–

More Johnson & Johnson figures

See a number that looks wrong?